Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Bayer plans US expansion despite blood thinner drug setback
08:15pm, Monday, 08'th Jan 2024
Germany's Bayer will continue its expansion into the U.S. despite its November announcement that its promising blood thinner candidate failed to demonstrate superiority over a competing medicine, the
Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies
12:47pm, Monday, 08'th Jan 2024
Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.
Moderna, Bayer-backed genetic therapies company files for IPO
12:04pm, Monday, 08'th Jan 2024
Metagenomi Technologies, a startup developing treatments for genetic diseases backed by Moderna Therapeutics Inc (NASDAQ:MRNA) and Bayer AG (ETR:BAYN, OTC:BAYZF), filed for a US IPO on Friday. Foun
Bayer's menopausal relief drug succeeds in late-stage trial
02:35am, Monday, 08'th Jan 2024
Bayer said its menopausal relief drug eased hot flashes and improved sleep in two late-stage trials, much-needed good news for the German group's pharmaceuticals unit that is reeling from a recent dev
46 Ideal 2024 Fortune And Barron's DiviDogs
03:02am, Sunday, 07'th Jan 2024
In December 2023 - January 2024, Barron's/Fortune analysts-reporters combined to list three sets of stocks: (1) Top 100 of first-ever Euro Fortune 500; (2) 13 Inflation-Proof 2024 stocks; (3) Barron's
Up To 10% Yields: My Top 10 High Dividend Yield Companies For January 2024
07:15am, Saturday, 06'th Jan 2024
High dividend yield companies are essential components within a well-balanced and diversified dividend portfolio, particularly for those seeking to generate substantial additional income via dividends
Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?
12:46pm, Friday, 29'th Dec 2023
Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.
MustGrow Biologics gives more detail on Bayer AG collaboration
08:31am, Wednesday, 13'th Dec 2023
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) has disclosed further details about its recently announced collaboration agreement with Bayer AG (ETR:BAYN, OTC:BAYZF) following questions received
MustGrow signs commercial license agreement with Bayer for biocontrol technologies in EMEA region
08:14am, Monday, 11'th Dec 2023
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) has announced a collaboration agreement with Bayer AG (ETR:BAYN, OTC:BAYZF) that focuses on the soil applications of MustGrow's mustard-based biocon
Bayer Isn't Dead
01:21pm, Wednesday, 06'th Dec 2023
Bayer AG's financial results show weakness, primarily due to temporary impact from its crop sciences business. Despite challenges, the company's outlook predicts continued respectable performance. Bay
Bayer ordered to pay $3.5 million in latest Roundup weedkiller trial
07:07pm, Tuesday, 05'th Dec 2023
Bayer was ordered on Tuesday to pay nearly $3.5 million by a Philadelphia jury that found the company's Roundup weedkiller caused a woman's cancer, the company said, the latest in a string of trial lo
As Bayer confronts mounting Roundup losses, all eyes on Philadelphia trial
06:09am, Monday, 04'th Dec 2023
With Bayer facing investor pressure to resolve thousands of lawsuits over its Roundup weedkiller after being hit with $2 billion in verdicts in recent weeks, all eyes are on a trial wrapping up in Phi
3 Battered Blue-Chip Stocks to Sell in December
06:30am, Tuesday, 28'th Nov 2023
The market continues to rip higher in November, with the S&P 500 up 9% since Halloween. However, not all stocks are participating in the rally.
Exclusive: Bayer holds call with bond investors after raft of bad news
05:41pm, Wednesday, 22'nd Nov 2023
Bayer held a call with investors on Monday after a raft of bad news led some of them to question whether the German group had been upfront about its prospects ahead of a $5.75 billion bond issuance, t
Bayer (BAYRY) Stops Heart Drug Study Due to Lack of Efficacy
01:32pm, Monday, 20'th Nov 2023
Bayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation.
